title: Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.
abstract: We investigated the medical and nursing records of 19 patients with unresectable advanced recurrent colorectal cancers treated using oxaliplatin and capecitabine(CapeOX)with or without bevacizumab at the outpatient tumor center of Showa UniversityHospital between November 1, 2009 and November 30, 2011, to clarifydifferences in the incidence of injection site reactions according to the use or non-use of an intravenous infusion solution warming device. Vascular pain and other injection site reactions occurred in 13 patients(68.4%). Injection site reactions occurred in 33 of the total of 77 chemotherapytreatments (42.9%). No difference in incidence of injection site reactions was seen according to whether the intravenous infusion solution warmer was used. The most common time to onset of injection site reactions after commencing oxaliplatin administration was 60-90 min, and symptoms were seen to decrease when non-steroidal anti-inflammatorydrugs were coadministered. We intend to leverage these studyfindings to demonstrate the mechanism of onset for injection site reactions and to propose measures for handling adverse drug reactions.
authors.affiliation: Division of Drug Information Analytics, Dept. of Drug Information, Showa University School of Pharmacy.
authors.forename: Satoko
authors.initials: S
authors.lastname: Handa
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kuroiwa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Miyano
authors.forename: Hisanori
authors.initials: H
authors.lastname: Shimizu
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kamei
authors.forename: Hiromi
authors.initials: H
authors.lastname: Takei
authors.forename: Hiroko
authors.initials: H
authors.lastname: Sonou
authors.forename: Hitomi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: JunIchiro
authors.initials: J
authors.lastname: Murayama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sato
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Kato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D000069287:Capecitabine / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D012008:Recurrence
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000069287:Capecitabine